Products & Services>> Research and Consulting>> Pharmaceutical Product Launch

Pharmaceutical Product Launch

Overview

You’re preparing to bring a new product to market?Congratulations, but here’s your reality:

Nearly $3 billion will have been spent in actual dollars and time when your new drug comes to market
Fewer drugs are gaining approval, as regulatory agencies focus on the safety and efficacy of the products being brought forth for consideration.
This is the age of specialty launches and annual peak revenues for many drugs will never find blockbuster status.

Knowing these three things, many launch teams find themselves struggling with a host of questions – as they know they must get their launch right or face imminent failure.

What critical marketing activities are needed to successfully launch a new product?

When should these activities be initiated and completed?

Who (global strategy team vs. the all-important U.S. team) is primarily responsible for carrying out these activities?

Where should decision-making authorities (positioning, branding, pricing, etc.) reside?

How much should be spent on key activities at different stages of the product development and launch cycle?

What business models and structures work best to serve different market types?

What sub-structures help foster productive working relationships across groups (Marketing, Medical Affairs, Field Sales, etc.) and avoid any overlap or redundancies from Global Teams to U.S. Teams?.

Know more

What lessons can I learned from best-in-class launches and teams?

What staffing levels are required for marketing teams at different phases?

What human resource capabilities and competencies are required for success in different market types and therapeutic areas?

What roles and responsibilities support accountability, fast-response to changing market conditions and launch team agility?

How do teams ensure early, adequate and consistent resource investment for marketing support across the development-to-market-entry cycle?

Less ⇧

Christopher Bogan

President and CEO

Chris has 26 years of experience in helping U.S. companies bring new biopharmaceutical products to market. Over that time, he has helped dozens of new brands launch assets totaling hundreds of billions of dollars.

Phone: (919)-767-9228

View Complimentary Research Sample

Launching A Blockbuster - A Best Practice Article featured in The Pharmaceutical Executive Magazine (ID WP-34)

Pharmaceutical Marketing: Re-launch Excellence White Paper (ID WP-26)

Benchmarking Critical New Product Launch Staffing, Investments and Activities & Their Sequencing: Understanding High-Priority Commercial and Medical Activities (ID WP-48)

Our Role

Companies with the questions above often seek out advice from Best Practices. We have helped hundreds of brand teams during the past 25 years successfully bring their drugs to market. Our ongoing research and studies show that focused planning can shape a product’s true market potential and dramatically increase its lifetime economic value.

Know more

Our extensive Launch Assets Database contains launch benchmarks, processes and strategies from more than 100 leading brands for commercial, medical affairs and managed care teams.

Best Practices supports pharmaceutical launch teams by delivering budget and staffing benchmarks that executives use to adjust their own launch spends and activity timelines prior to and after launch. Our goal is to help launch executives identify opportunities for structural and operational improvements.

Less ⇧

Your Benefits

We can help you create your launch playbook -- providing years of insights from successful launches, supported by budget and staffing benchmarks.

Know more

COMPARE

Individual launch plan components against industry benchmarks

ASSESS

Optimization of sales and marketing plans, including marketing mix and activity allocation

CALIBRATE

Strategy to drive global/regional plans

CONDUCT

Launch budget and staffing resource assessments

CREATE

Strategy to engage key internal and external stakeholders

IDENTIFY

Successful innovative product launch tactics and strategies

Less ⇧

Best Practices' Launch Assets Database Contains Benchmarks and Insights for

Effient

Gardasil

Effexor

Incivek

Tecfidera

Harvoni

Sovaldi

Diovan

Cozaar

Xalatan

Zoloft

Allegra

Paxil

Lipitor

Fosamax

Norvasc

Botox

Lescol

Trovan

Zofran

Gleevec

Zithromax

Wellbutrin

Requip

Cymbalta

Flomax

Exubera

Slentrol

Januvia

Nexavar

Erbitux

Avastin

Vectibix

Onglyza

Imitrex/Imigran

Rituxan

Crestor

Spiriva

Xigris

Levitra

Nexium

Seroquel

Byetta

Advair

Celebrex

KEYTRUDA Case Study: How Merck Used Bold Indications Planning Coupled with Expansive Clinical Trials to Lift a Second-To-Market Product into the Annals of Blockbuster Launch History

This case study reveals how Merck turned a near-failure into a cornerstone of cancer treatment throu... (ID PSM-392)
Companies Profiled: Merck, Advaxis, Ascentage Pharma, Astellas, read more ...

Price: $3000.00

Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease

This case study reviews Tepezza’s trajectory to achieving blockbuster status in a rare disease autoi... (ID PSM-389)
Companies Profiled: Amgen, Horizon Therapeutics

Price: $3900.00

Case Study: How argenx Broke into a Captive Market to Begin Dislodging an Entrenched Market Leader

This case study reviews VYVGART’s trajectory to breaking into the captive generalized Myasthenia Gra... (ID PSM-388)
Companies Profiled: argenx, Alexion Pharmaceuticals, AstraZeneca

Price: $3900.00

Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine

Managing Hostile Stakeholders During Launch

This report probes successful practices for managing hostile stakeholders during the launch of a bre... (ID PSM-380)
Companies Profiled: Bayer, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, read more ...

Price: $3800.00

Best Practices Pharma Launch Playbook

This comprehensive Best Practices, LLC launch playbook provides the requisite insights for an effect... (ID PB-100)
Companies Profiled: Abbott, AbbVie, actavis, Actelion, read more ...

Price: $79900.00

Disease Awareness Program Excellence: Structure, Activities, and Resources Needed for Effective Pipeline Support

This benchmarking report highlights effective practices around the timing, investment, and activitie... (ID PSM-377)
Companies Profiled: AbbVie, Adamas Pharmaceuticals, AstraZeneca, Bayer, read more ...

Price: $5500.00

Pharmaceutical Product Launch

Overview

Know more

View Complimentary Research Sample

Our Role

Know more

Your Benefits

Know more

COMPARE

ASSESS

CALIBRATE

CONDUCT

CREATE

IDENTIFY

Best Practices' Launch Assets Database Contains Benchmarks and Insights for

RELATED RESEARCH

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BB095D8509532B1B652581A80044D899
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/BB095D8509532B1B652581A80044D899?opendocument
18
19opendocument
20172.70.126.20
21
22
23116639.0ncwlf7ax.asia
24/bestp/domrep.nsf
25RC